In an acute promyelocytic leukemia (APL) transplantable mouse model, we previously reported the presence of antibodies recognizing PML-RARα and RARα in the sera of ATRA-treated mice. To evaluate this immune response, we determined the prevalence of anti-RARα antibodies in a cohort of 48 APL mice, treated by ATRA (n=24) or by placebo pellets (n=24), and in a preliminary subset of 9 APL patients using a specific Enzyme-Linked-Immunosorbent-Assay (ELISA). In APL mice, significantly higher antibody levels were observed at the latest time-points (days 48-58 levels superior to days 15-18 or days 28-38 levels). Antibody levels were higher in ATRA-treated mice than in placebo-treated mice and were also predictive of better survival. In the APL patients, anti-RARα antibodies were detected at diagnosis and after maintenance therapy, reminiscent of the ATRA-treated APL mice. Antinuclear or anti-neutrophil cytoplasmic auto-antibodies were also detected. These data reveal for the first time that in APL patients an immune response may be detected at diagnosis and enhanced after maintenance therapy.
Introduction
Acute promyelocytic leukemia (APL) is characterized by a differentiation block at the promyelocytic stage and by a reciprocal chromosomal translocation, t(15;17)(q24;q21) fusing the promyelocytic leukemia gene (PML) with the retinoic acid receptor alpha (RARα) gene 1 . Treatment with all-trans retinoic acid (ATRA) and chemotherapy induces complete remissions in 90% of PML-RARα positive APL patients through ATRA induced differentiation of the leukemic cells and their subsequent elimination by apoptosis 2 . Apart from their known effects on cell differentiation, retinoids also play an important role in infection and immune functions 3 . In hypovitaminosis A animal models and in vitamin A deficient children, alterations in antiviral, anti-bacterial or anti-parasite responses have been shown [3] [4] [5] .
In an APL transplantable mouse model which shares the promyelocytic features and response to ATRA of human APL 6 , we have previously reported the presence of antibodies in ATRA-treated-mice sera 7 . By western-blot analysis, we showed that these antibodies recognized mouse and human RARα from spleen and HL-60 cells respectively, as well as PML-RARα from mice spleen and NB4 leukemic cells. We hypothesized that such adjuvant effects of ATRA might also participate in the efficacy of ATRA in patients with APL especially during maintenance therapy when the tumor burden is low and immunocompetency restored 2 .
The aim of our study was therefore to further characterize anti-RARα antibody production in APL mice as well as in patients with APL. In APL patients, antibodies to
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Methods
The animal model of APL transplanted mice and ATRA therapy was set up as already described 6, 7 . Data from three protocols which did not differ in their response to ATRA were pooled. Placebo (n=24) and ATRA-treated APL (n=24) mice died from day 18 to 29 (median 26 days), and from day 28 to 95 (median 55 days) respectively, as already reported 6, 7 .
Antibodies against RARα were detected by an ELISA test at different time-intervals as previously described 7 . For each mouse serum, specific absorbance (SA) was calculated as the difference between duplicates of mean absorbance with and without GST-RARα. In An ELISA test was performed in sera from 9 patients with APL to detect the presence of anti-RARα antibodies. Anti-nuclear (ANA) and anti-neutrophil cytoplasmic (ANCA) autoantibodies were measured by indirect immuno-fluorescence. The 9 patients studied related to the availability of stored sera at diagnosis and after 2-year maintenance therapy 2 .
Patients were enrolled in APL trials : patients 3,5,8 from APL93 and patients 1,2,4,6,7,9 from APL2000 trial. In these trials informed consent was obtained to use stored samples.
For all patients sera were stored in similar conditions at -30°C and thawed once. 18 healthy subjects served as controls.
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Results and discussion

Description of the anti-RARα antibody production in APL mice
As we have previously reported, anti-RARα antibodies were detected in ATRAtreated APL mice For personal use only. on September 14, 2017. by guest www.bloodjournal.org From with a level lower than the median D"18" AU (0.26), versus 49 days for mice with a level higher than the median D"18" AU (log-rang test, p=0.0319).
Description of the anti-RARα antibody production in APL patients
To provide relevance to the pre-clinical data obtained in APL mice, anti-RARα antibodies were retrospectively analyzed by ELISA in 9 APL patients. All patients were in complete remission at the time of post-maintenance treatment study. For the first time, anti-RARα antibodies were detected both at diagnosis and after maintenance therapy in APL patients, and the antibody production followed a timedependent pattern similar to the kinetics of anti-RARα antibodies observed in APL mice ( Figure 1d and Table 1 ). In 5 out of 9 patients anti-RARα antibodies levels increased with time. Of note, among the 4 patients in whom no increase in anti-RARα antibody levels was seen, 3 had already high levels of antibodies at diagnosis.
Interestingly, other autoimmunity manifestations were observed in these patients. At diagnosis, seven (78%) were either positive for antinuclear (ANA) or anti-neutrophil cytoplasmic (ANCA) auto-antibodies and all patients were either ANA or ANCA positive after maintenance therapy ( Table 1 ). This proportion was higher than that expected in the general population (13.3% and 0-1.8% of healthy persons may present ANA 9 or ANCA auto-antibodies 10 respectively). Thus APL patients present frequent auto-antibodies especially after maintenance therapy. 
